However, overweight and obesity have emerged as an important issue in the CF population due to advancements in therapy and increased longevity, especially in recent years with the introduction of CF transmembrane conductance regulator (CFTR) modulator therapies [7,8,9,10]. This evidence concerns the gene CFTR and cystic fibrosis.